{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:55:21Z","timestamp":1792601721019,"version":"4.5.0"},"reference-count":61,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPD"],"published-print":{"date-parts":[[2020,7,28]]},"DOI":"10.3233\/jpd-202004","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T04:55:56Z","timestamp":1591160156000},"page":"875-891","source":"Crossref","is-referenced-by-count":125,"title":["GDNF and Parkinson\u2019s Disease: Where Next? A Summary from a Recent Workshop"],"prefix":"10.1177","volume":"10","author":[{"given":"Roger A.","family":"Barker","sequence":"first","affiliation":[{"name":"Cambridge Centre for Brain Repair, Department of Clinical Neuroscience and WT-MRC Cambridge Stem Cell Institute, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Bj\u00f6rklund","sequence":"additional","affiliation":[{"name":"Wallenberg Neuroscience Center, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don M.","family":"Gash","sequence":"additional","affiliation":[{"name":"Professor Emeritus of Neuroscience, University of Kentucky, Lexington, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Whone","sequence":"additional","affiliation":[{"name":"Translational Health Sciences, Bristol Medical School, University of Bristol and Neurological and Musculoskeletal Sciences Division, North Bristol NHS Trust, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Van Laar","sequence":"additional","affiliation":[{"name":"Brain Neurotherapy Bio Inc., Oakland, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Kordower","sequence":"additional","affiliation":[{"name":"Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystof","family":"Bankiewicz","sequence":"additional","affiliation":[{"name":"Neurological Surgery, Gilbert and Kathryn Mitchell Endowed Chair, Director, Brain Health and Performance Center, The Ohio State University, Department of Neurological Surgery, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Kieburtz","sequence":"additional","affiliation":[{"name":"Center for Health & Technology, and the Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart","family":"Saarma","sequence":"additional","affiliation":[{"name":"Institute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Booms","sequence":"additional","affiliation":[{"name":"Herantis Pharma Plc, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri J.","family":"Huttunen","sequence":"additional","affiliation":[{"name":"Herantis Pharma Plc, Finland"},{"name":"Neuroscience Center, HiLIFE, University of Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian P.","family":"Kells","sequence":"additional","affiliation":[{"name":"Brain Neurotherapy Bio Inc., Oakland, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo S.","family":"Fiandaca","sequence":"additional","affiliation":[{"name":"Brain Neurotherapy Bio Inc., Oakland, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Jon","family":"Stoessl","sequence":"additional","affiliation":[{"name":"Pacific Parkinson\u2019s Research Centre & Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Eidelberg","sequence":"additional","affiliation":[{"name":"Center for Neurosciences, The Feinstein Institutes for Medical Research, Manhasset, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Federoff","sequence":"additional","affiliation":[{"name":"School of Medicine, Susan and Henry College of Health Sciences, University of California, Irvine and CEO, Aspen Neuroscience, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merja H.","family":"Voutilainen","sequence":"additional","affiliation":[{"name":"Institute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Dexter","sequence":"additional","affiliation":[{"name":"Parkinson\u2019s UK, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Eberling","sequence":"additional","affiliation":[{"name":"The Michael J. Fox Foundation for Parkinson\u2019s Research, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrik","family":"Brundin","sequence":"additional","affiliation":[{"name":"Center for Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndsey","family":"Isaacs","sequence":"additional","affiliation":[{"name":"The Cure Parkinson\u2019s Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Mursaleen","sequence":"additional","affiliation":[{"name":"The Cure Parkinson\u2019s Trust, London, UK"},{"name":"School of Life Sciences, University of Westminster, UK and School of Pharmacy, University College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eros","family":"Bresolin","sequence":"additional","affiliation":[{"name":"The Cure Parkinson\u2019s Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Carroll","sequence":"additional","affiliation":[{"name":"University of Plymouth, Faculty of Health, Plymouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alasdair","family":"Coles","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, University of Cambridge, Addenbrooke\u2019s Hospital, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Fiske","sequence":"additional","affiliation":[{"name":"The Michael J. Fox Foundation for Parkinson\u2019s Research, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Matthews","sequence":"additional","affiliation":[{"name":"The Cure Parkinson\u2019s Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Codrin","family":"Lungu","sequence":"additional","affiliation":[{"name":"Division of Clinical Research, National Institute of Neurological Disorders and Stroke, Rockville, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K.","family":"Wyse","sequence":"additional","affiliation":[{"name":"The Cure Parkinson\u2019s Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Stott","sequence":"additional","affiliation":[{"name":"The Cure Parkinson\u2019s Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony E.","family":"Lang","sequence":"additional","affiliation":[{"name":"The Edmond J Safra Program in Parkinson\u2019s Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, and the Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JPD-202004_ref1","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/ejn.14102","article-title":"Trophic factors for Parkinson\u2019s disease: Where are we and where do we go from here?","volume":"49","author":"Paul","year":"2019","journal-title":"Eur J Neurosci"},{"key":"10.3233\/JPD-202004_ref2","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.3233\/JPD-202004_ref3","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1126\/science.8493557","article-title":"GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons","volume":"260","author":"Lin","year":"1993","journal-title":"Science"},{"key":"10.3233\/JPD-202004_ref4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1212\/WNL.60.1.69","article-title":"Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD","volume":"60","author":"Nutt","year":"2003","journal-title":"Neurology"},{"key":"10.3233\/JPD-202004_ref5","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/384467a0","article-title":"Neurturin, a relative of glial-cell-line-derived neurotrophic factor","volume":"384","author":"Kotzbauer","year":"1996","journal-title":"Nature"},{"key":"10.3233\/JPD-202004_ref6","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrn812","article-title":"The GDNF family: Signalling, biological functions and therapeutic value","volume":"3","author":"Airaksinen","year":"2002","journal-title":"Nat Rev Neurosci"},{"key":"10.3233\/JPD-202004_ref7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0006-8993(94)01366-P","article-title":"GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo","volume":"672","author":"Kearns","year":"1995","journal-title":"Brain Res"},{"key":"10.3233\/JPD-202004_ref8","doi-asserted-by":"crossref","first-page":"8935","DOI":"10.1073\/pnas.92.19.8935","article-title":"Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion","volume":"92","author":"Sauer","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JPD-202004_ref9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/373335a0","article-title":"Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo","volume":"373","author":"Tomac","year":"1995","journal-title":"Nature"},{"key":"10.3233\/JPD-202004_ref10","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/373339a0","article-title":"Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain","volume":"373","author":"Beck","year":"1995","journal-title":"Nature"},{"key":"10.3233\/JPD-202004_ref11","first-page":"1181","article-title":"Functional effects of GDNF in normal rat striatum: Presynaptic studies using in vivo electrochemistry and microdialysis","volume":"279","author":"Hebert","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.3233\/JPD-202004_ref12","first-page":"1396","article-title":"Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys","volume":"282","author":"Zhang","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.3233\/JPD-202004_ref13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1006\/exnr.2000.7571","article-title":"Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin","volume":"168","author":"Hamilton","year":"2001","journal-title":"Exp Neurol"},{"key":"10.3233\/JPD-202004_ref14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1083\/jcb.201009136","article-title":"Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, and artemin","volume":"192","author":"Bespalov","year":"2011","journal-title":"J Cell Biol"},{"key":"10.3233\/JPD-202004_ref15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0006-8993(98)01244-X","article-title":"GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys","volume":"817","author":"Gerhardt","year":"1999","journal-title":"Brain Res"},{"key":"10.3233\/JPD-202004_ref16","doi-asserted-by":"crossref","first-page":"7206","DOI":"10.1523\/JNEUROSCI.16-22-07206.1996","article-title":"Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson\u2019s disease","volume":"16","author":"Winkler","year":"1996","journal-title":"J Neurosci"},{"key":"10.3233\/JPD-202004_ref17","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1046\/j.1460-9568.2000.00274.x","article-title":"Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor","volume":"12","author":"Kirik","year":"2000","journal-title":"Eur J Neurosci"},{"key":"10.3233\/JPD-202004_ref18","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1046\/j.1460-9568.1999.00566.x","article-title":"Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson\u2019s disease after administration into the striatum or the lateral ventricle","volume":"11","author":"Rosenblad","year":"1999","journal-title":"Eur J Neurosci"},{"key":"10.3233\/JPD-202004_ref19","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0197-4580(02)00022-2","article-title":"Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys","volume":"23","author":"Maswood","year":"2002","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JPD-202004_ref20","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1089\/hum.2008.201","article-title":"Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys","volume":"20","author":"Eberling","year":"2009","journal-title":"Hum Gene Ther"},{"key":"10.3233\/JPD-202004_ref21","doi-asserted-by":"crossref","first-page":"9567","DOI":"10.1523\/JNEUROSCI.0942-10.2010","article-title":"Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF","volume":"30","author":"Kells","year":"2010","journal-title":"J Neurosci"},{"key":"10.3233\/JPD-202004_ref22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00401-017-1788-5","article-title":"Parkinson\u2019s disease: Experimental models and reality","volume":"135","author":"Jiang","year":"2018","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JPD-202004_ref23","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1093\/brain\/awr149","article-title":"GDNF fails to exert neuroprotection in a rat alpha-synuclein model of Parkinson\u2019s disease","volume":"134","author":"Decressac","year":"2011","journal-title":"Brain"},{"key":"10.3233\/JPD-202004_ref24","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.nbd.2004.06.008","article-title":"Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson\u2019s disease","volume":"17","author":"Lo Bianco","year":"2004","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JPD-202004_ref25","doi-asserted-by":"crossref","first-page":"163ra156","DOI":"10.1126\/scitranslmed.3004676","article-title":"alpha-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons","volume":"4","author":"Decressac","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.3233\/JPD-202004_ref26","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/j.1471-4159.2010.06841.x","article-title":"Nurr1 regulates RET expression in dopamine neurons of adult rat midbrain","volume":"114","author":"Galleguillos","year":"2010","journal-title":"J Neurochem"},{"key":"10.3233\/JPD-202004_ref27","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/cne.20828","article-title":"Nurr1 in Parkinson\u2019s disease and related disorders","volume":"494","author":"Chu","year":"2006","journal-title":"J Comp Neurol"},{"key":"10.3233\/JPD-202004_ref28","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.ymthe.2017.04.018","article-title":"Alpha-synuclein mRNA is not increased in sporadic PD and alpha-synuclein accumulation does not block GDNF signaling in Parkinson\u2019s disease and disease models","volume":"25","author":"Su","year":"2017","journal-title":"Mol Ther"},{"key":"10.3233\/JPD-202004_ref29","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/1531-8249(199909)46:3<419::AID-ANA21>3.0.CO;2-Q","article-title":"Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson\u2019s disease","volume":"46","author":"Kordower","year":"1999","journal-title":"Ann Neurol"},{"key":"10.3233\/JPD-202004_ref30","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm850","article-title":"Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease","volume":"9","author":"Gill","year":"2003","journal-title":"Nat Med"},{"key":"10.3233\/JPD-202004_ref31","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3171\/jns.2005.102.2.0216","article-title":"Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor","volume":"102","author":"Slevin","year":"2005","journal-title":"J Neurosurg"},{"key":"10.3233\/JPD-202004_ref32","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm0705-703","article-title":"Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain","volume":"11","author":"Love","year":"2005","journal-title":"Nat Med"},{"key":"10.3233\/JPD-202004_ref33","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ana.20737","article-title":"Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease","volume":"59","author":"Lang","year":"2006","journal-title":"Ann Neurol"},{"key":"10.3233\/JPD-202004_ref34","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1177\/01926230701481899","article-title":"Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF in rhesus monkeys","volume":"35","author":"Hovland","year":"2007","journal-title":"Toxicol Pathol"},{"key":"10.3233\/JPD-202004_ref35","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.expneurol.2006.07.015","article-title":"Point source concentration of GDNF may explain failure of phase II clinical trial","volume":"202","author":"Salvatore","year":"2006","journal-title":"Exp Neurol"},{"key":"10.3233\/JPD-202004_ref36","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.20374","article-title":"Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: A two-year outcome study","volume":"57","author":"Patel","year":"2005","journal-title":"Ann Neurol"},{"key":"10.3233\/JPD-202004_ref37","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1212\/WNL.0b013e3182a55ea5","article-title":"Benefits of putaminal GDNF infusion in Parkinson disease are maintained after GDNF cessation","volume":"81","author":"Patel","year":"2013","journal-title":"Neurology"},{"key":"10.3233\/JPD-202004_ref38","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/brain\/awz023","article-title":"Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson\u2019s disease","volume":"142","author":"Whone","year":"2019","journal-title":"Brain"},{"key":"10.3233\/JPD-202004_ref39","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3233\/JPD-191576","article-title":"Extended treatment with glial cell line-derived neurotrophic factor in Parkinson\u2019s disease","volume":"9","author":"Whone","year":"2019","journal-title":"J Parkinsons Dis"},{"key":"10.3233\/JPD-202004_ref40","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1097\/RLU.0000000000000383","article-title":"18F-DOPA, a clinically available PET tracer to study brain inflammation?","volume":"39","author":"Sala","year":"2014","journal-title":"Clin Nucl Med"},{"issue":"2","key":"10.3233\/JPD-202004_ref41","doi-asserted-by":"crossref","first-page":"T27","DOI":"10.1016\/j.neuroimage.2008.11.012","article-title":"Real-time MR imaging of adeno-associated viral vector delivery to the primate brain","volume":"47","author":"Fiandaca","year":"2009","journal-title":"Neuroimage"},{"key":"10.3233\/JPD-202004_ref42","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ymthe.2006.05.005","article-title":"Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC","volume":"14","author":"Bankiewicz","year":"2006","journal-title":"Mol Ther"},{"key":"10.3233\/JPD-202004_ref43","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.nbd.2011.10.004","article-title":"Glial-derived neurotrophic factor gene transfer for Parkinson\u2019s disease: Anterograde distribution of AAV2 vectors in the primate brain","volume":"48","author":"Kells","year":"2012","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JPD-202004_ref44","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/gt.2012.27","article-title":"Axonal transport of adeno-associated viral vectors is serotype-dependent","volume":"20","author":"Salegio","year":"2013","journal-title":"Gene Ther"},{"key":"10.3233\/JPD-202004_ref45","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1474-4422(08)70065-6","article-title":"Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson\u2019s disease: An open-label, phase I trial","volume":"7","author":"Marks","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.3233\/JPD-202004_ref46","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","article-title":"Gene delivery of AAV2-neurturin for Parkinson\u2019s disease: A double-blind, randomised, controlled trial","volume":"9","author":"Marks","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.3233\/JPD-202004_ref47","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.nbd.2015.03.023","article-title":"Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with alpha-synucleinopathies","volume":"78","author":"Bartus","year":"2015","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JPD-202004_ref48","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ana.24436","article-title":"Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial","volume":"78","author":"Warren Olanow","year":"2015","journal-title":"Ann Neurol"},{"key":"10.3233\/JPD-202004_ref49","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/mds.27724","article-title":"Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson\u2019s disease","volume":"34","author":"Heiss","year":"2019","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-202004_ref50","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ana.25450","article-title":"Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson\u2019s disease","volume":"85","author":"Christine","year":"2019","journal-title":"Ann Neurol"},{"key":"10.3233\/JPD-202004_ref51","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jconrel.2016.02.034","article-title":"AAV viral vector delivery to the brain by shape-conforming MR-guided infusions","volume":"240","author":"Bankiewicz","year":"2016","journal-title":"J Control Release"},{"key":"10.3233\/JPD-202004_ref52","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1093\/brain\/awt192","article-title":"Disease duration and the integrity of the nigrostriatal system in Parkinson\u2019s disease","volume":"136","author":"Kordower","year":"2013","journal-title":"Brain"},{"key":"10.3233\/JPD-202004_ref53","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ejmp.2018.06.637","article-title":"The effects of image reconstruction algorithms on topographic characteristics, diagnostic performance and clinical correlation of metabolic brain networks in Parkinson\u2019s disease","volume":"52","author":"Tomse","year":"2018","journal-title":"Phys Med"},{"key":"10.3233\/JPD-202004_ref54","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/ana.24781","article-title":"Specifically neuropathic Gaucher\u2019s mutations accelerate cognitive decline in Parkinson\u2019s","volume":"80","author":"Liu","year":"2016","journal-title":"Ann Neurol"},{"key":"10.3233\/JPD-202004_ref55","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/brain\/aws318","article-title":"Glucocerebrosidase mutations influence the natural history of Parkinson\u2019s disease in a community-based incident cohort","volume":"136","author":"Winder-Rhodes","year":"2013","journal-title":"Brain"},{"key":"10.3233\/JPD-202004_ref56","doi-asserted-by":"crossref","first-page":"fcaa046","DOI":"10.1093\/braincomms\/fcaa046","article-title":"The Parkinson\u2019s Disease Comprehensive Response (PDCORE): A composite approach integrating three standard outcome measures","author":"Luz","year":"2020","journal-title":"Brain Commun"},{"key":"10.3233\/JPD-202004_ref57","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.expneurol.2009.07.002","article-title":"Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons","volume":"219","author":"Piltonen","year":"2009","journal-title":"Exp Neurol"},{"key":"10.3233\/JPD-202004_ref58","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.nbd.2016.07.008","article-title":"Developing therapeutically more efficient Neurturin variants for treatment of Parkinson\u2019s disease","volume":"96","author":"Runeberg-Roos","year":"2016","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JPD-202004_ref59","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/mds.27943","article-title":"Glial cell line-derived neurotrophic factor receptor Rearranged during transfection agonist supports dopamine neurons in vitro and enhances dopamine release in vivo","volume":"35","author":"Mahato","year":"2020","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-202004_ref60","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nature05957","article-title":"Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo","volume":"448","author":"Lindholm","year":"2007","journal-title":"Nature"},{"key":"10.3233\/JPD-202004_ref61","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1177\/0963689719840290","article-title":"CDNF protein therapy in Parkinson\u2019s disease","volume":"28","author":"Huttunen","year":"2019","journal-title":"Cell Transplant"}],"container-title":["Journal of Parkinson's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JPD-202004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:48:18Z","timestamp":1777610898000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JPD-202004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,28]]},"references-count":61,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jpd-202004","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,28]]}}}